National University of Singapore, Singapore
Disclosure(s): AMR Action Fund: Board Member (Ongoing); Entasis: Board Member (Ongoing); Merck: Board Member (Ongoing); Pfizer: Board Member (Ongoing); QPex: Board Member (Ongoing); Venatorx: Board Member (Ongoing)
30 - Challenging Cases in Infectious Diseases
Thursday, October 12, 2023
10:30 AM – 11:45 AM US ET
256 - Reviving the Antimicrobial Pipeline: Costs, Challenges and Opportunities
Saturday, October 14, 2023
1:45 PM – 3:00 PM US ET
2869 - Facilitating Adaptive Clinical Trial Design for Anti-Infectives
Saturday, October 14, 2023
2:10 PM – 2:35 PM US ET